-- 任天堂(東京證券交易所代號:7974)2026財年淨利年增52%,主要得益於銷售額的強勁成長,但預計未來一年業績將有所下滑。 這家總部位於京都的遊戲製造商週五向東京證券交易所披露,截至2026年3月31日的財年,其淨利潤從上一財年的2,788億日圓增至4,241億日圓。 這一數字超過了Visible Alpha分析師先前預測的4,186億日圓。 每股盈餘從上一財年的239.47日圓躍升至364.51日圓。 Visible Alpha分析師先前預測的每股盈餘為358.51日圓。 營收飆升99%,從上一財年的1.165兆日圓增加至2.313兆日圓。儘管有所增長,但這一數字仍未達到Visible Alpha分析師預測的2.322兆日圓。 包括硬體和軟體在內的專用電玩平台銷售額飆升107%,從1.084兆日圓增至2.240兆日圓。 其3月發售的《精靈寶可夢:寶可夢世界》(Pokémon Pokopia)遊戲硬體銷量躍升至1,990萬台,而其《瑪利歐賽車世界》(Mario Kart World)軟體銷量(含捆綁銷售)達到1,470萬份。 任天堂表示,已上市10年的任天堂Switch遊戲機銷售量總計380萬台,較2025財年的1,080萬台下降65%。 由於電影相關收入下降,智慧財產權銷售額年減9.7%至735億日圓。 其春季檔電影《超級瑪利歐銀河大電影》(Super Mario Galaxy Movie)上映前四周全球票房收入達8億美元。 這家遊戲製造商預測,2027財年淨利潤將暴跌27%至3100億日元,銷售額將下滑11%至2.050萬億日元,這其中已計入包括內存等零部件價格上漲和關稅在內的1000億日元的影響。 該公司表示,Nintendo Switch 2的銷量在2026財年達到1990萬台,預計2027財年將下降17%至1650萬台,但這仍然表明該設備在上市第二年仍保持著「穩定的市場接受度」。 該公司預計,Nintendo Switch的銷量在2027財年將下降47%至200萬台。 此外,該公司週五宣布調整其Nintendo Switch和Nintendo Switch 2遊戲機在國內外的價格。 在日本,自5月25日起,Switch 2的價格將上漲20%,從49,980日圓漲至59,980日圓。 Nintendo Switch的OLED版、標準版和Lite版的價格也將上漲。 在美國,任天堂將Switch 2的價格從449.99美元上調至499.99美元。這款新主機的價格調整將於9月1日起在加拿大和歐洲生效。 該公司維持了其Nintendo Switch在美國、加拿大和歐洲的價格不變,但警告稱,其他地區的Switch 2和標準版Switch的價格可能會進一步調整。 任天堂宣布派發每股177日圓的股息,是上一財年85日圓股息的兩倍多。 2027財年,任天堂的股息可能達到每股162日圓。
Related Articles
Jefferies Upgrades Devon Energy to Buy From Hold, Adjusts Price Target to $62 From $53
Devon Energy (DVN) has an average rating of overweight and mean price target of $59.67, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Telus Q1 Adjusted Earnings Edge Lower, But Beats Estimates
Telus (T.TO) reported Friday that first-quarter adjusted earnings edged lower but still beat forecasts.Adjusted net income, which most one-time items, contracted 8% to $356 million, or $0.23 per adjusted basic share, from $388 million, or $0.26 per share, in the prior year period. Analysts polled by FactSet had expected $0.22 per share.Consolidated operating revenue and other income edged down 1% to $5.0 billion, from $5.1 billion the year before, missing the $5.06 billion expected by analysts. Telus said higher consolidated service revenue growth of 1% was offset by lower Mobile equipment revenue and other income.The company reported total mobile and fixed customer growth of 262,000 driven by 12,000 mobile phone and 229,000 connected device net additions, along with 21,000 internet customer net additions, during the quarter.As of the end of the first quarter, healthcare lives covered in Telus Health were 169.6 million globally, up 93.1 million year over year. The increase also reflects the addition of 79.3 million lives covered from Telus' acquisition of Workplace Options last May. The company is reviewing strategic partnership opportunities for Telus and will use the proceeds from any monetization for deleveraging, chief executive Darren Entwhistle said.Telus will pay a regular quarterly dividend of $0.4184 per share on July 2, to shareholders of record on June 10.Telus separately announced that chief financial officer Doug French will retire on June 30. Gopi Chande, currently chief financial officer of Telus Digital and Telus Health, will assume the post on July 1. French will continue in an advisory capacity until July 31 and will chair the board of Telus' Terrion tower company.Telus shares were last seen down US$0.06, to US$12.84 in U.S. pre-market trading.
Market Chatter: Novo Nordisk India Sales Jump 40% in April After Wegovy, Ozempic Price Cuts
Novo Nordisk's diabetes and obesity drug sales recorded a sharp rise in India sales in April after it reduced prices of Wegovy and Ozempic to counter growing competition from generic semaglutide therapies, Bloomberg News reported Friday, citing Pharmarack data.Sales of Wegovy, Ozempic and partner-branded products climbed 40% monthly to 32,000 units in April, which was the first full month since the Danish pharmaceutical group lowered starter-dose prices by up to 48%, the report noted.India's overall GLP-1 market expanded 56% month over month in April to 414,000 units, driven by low-cost generic semaglutide products, the report noted. Eli Lilly remained the country's top-selling GLP-1 drugmaker.Novo Nordisk did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)